NCT02974569 (CSCAT2) is a clinical trial of Computer Symptom Capture Tool in Symptom Clusters, sponsored by Virginia Commonwealth University.

Who is sponsoring NCT02974569?

NCT02974569 is sponsored by Virginia Commonwealth University.

What drugs are being tested in NCT02974569?

Interventions in NCT02974569: Computer Symptom Capture Tool.

What condition does NCT02974569 study?

NCT02974569 studies Symptom Clusters, Cancer.

Is NCT02974569 still recruiting?

NCT02974569 is currently completed. Last updated 22 December 2017.

Last reviewed 2017-12-22 · How we verify

NCT02974569: CSCAT2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Improving Symptom Self-management in Adolescents & Young Adults With Cancer

Completed Last updated 22 December 2017

What this trial tests

trial testing Computer Symptom Capture Tool in Symptom Clusters in 30 participants. Completed in 25 October 2017.

Timeline

1 November 2016

Primary endpoint
25 October 2017

25 October 2017

Quick facts

Lead sponsor	Virginia Commonwealth University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	30
Start date	1 November 2016
Primary completion	25 October 2017
Estimated completion	25 October 2017
Sites	2 locations across United States

Drugs / interventions tested

Computer Symptom Capture Tool

Conditions studied

Symptom Clusters — all drugs for Symptom Clusters →
Cancer — all drugs for Cancer →

Sponsor

Virginia Commonwealth University

Who can join

Adults 15 to 29, any sex, with Symptom Clusters or Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the use of the Computerized Symptom Capture Tool (C-SCAT), which creates an image of the symptoms the participant is experiencing, for improving symptom self-management in adolescents and young adults with cancer. In this one-group trial, participants will complete the C-SCAT and use it during two clinic visits with their oncology providers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Virginia Commonwealth University trials

Trials by the same sponsor.

NCT05936931 — Young Adult-Mediated Intervention to Increase Colorectal Cancer Screening · NA · not yet recruiting
NCT07365839 — Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma · Phase 1 · not yet recruiting
NCT07178158 — Enhancing Addiction Treatment Through Psychoeducation · NA · not yet recruiting
NCT07531316 — Safety and Tolerability Study of VVZ-2471 in Healthy Volunteers · Phase 1 · not yet recruiting
NCT07426913 — Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02974569 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Virginia Commonwealth University
Last refreshed: 22 December 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02974569.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing